Trial
NCT03334487
Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer
Phase IIIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
AbbVie
Collaborators
—
Condition
Small Cell Lung Cancer
Intervention
Dexamethasone
Why stopped
Strategic considerations
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-12-26